Quantification of human complement factor H binding to asexual malaria blood stages by an enzyme-linked immunosorbent assay

[Display omitted] •ELISA validation for quantitative measurement of complement factorH (FH) cell surface binding.•Indirect assessment of stage-specific potential of FH-receptor proteins as vaccine candidates.•Malaria merozoites bind 10 times more FH molecules than early intracellular parasite blood... Full description

[Display omitted] •ELISA validation for quantitative measurement of complement factorH (FH) cell surface binding.•Indirect assessment of stage-specific potential of FH-receptor proteins as vaccine candidates.•Malaria merozoites bind 10 times more FH molecules than early intracellular parasite blood stages. The human complement system is the most effective defense mechanism of the human innate immune system. One major negative regulator of the alternative pathway in human blood is complement factor H (FH). It binds to autologous cells and thus, prevents complement attack against body-cells or tissues. Various pathogens are known to escape complement recognition by recruiting FH to provide protection against the host’s immune system. This immune evasion mechanism was recently qualitatively reported for asexual malaria blood stages. To indirectly evaluate the stage-specific potential of FH-receptor proteins as vaccine candidates, we quantified the FH molecules bound to the surface of different malaria blood stage parasites by Western blot and a commercially available FH-ELISA, which was originally designed to measure the FH concentration in human serum. Host-cell-free merozoites and intracellular mature schizont (here called segmenter) stages bind significantly more FH molecules than earlier parasite stages.